Today it was reported that a Director at Repligen Corp (NASDAQ: RGEN), Nicolas Barthelemy, exercised options to sell 6,580 RGEN shares at $39.85 a share, for a total transaction value of $358.1K.
In addition to Nicolas Barthelemy, 4 other RGEN executives reported Sell trades in the last month. This is Barthelemy’s first transaction since reporting a Buy transaction on RSD:LIFE back in December 2010
See today’s analyst top recommended stocks >>
Based on Repligen Corp’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $47.73 million and quarterly net profit of $2.74 million. In comparison, last year the company earned revenue of $32.46 million and had a net profit of $8.44 million. RGEN’s market cap is $2.38B and the company has a P/E ratio of 104.63. Currently, Repligen Corp has an average volume of 210.9K.
Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $52.00, reflecting a -5.2% downside.
The insider sentiment on Repligen Corp has been negative according to 29 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Repligen Corp. engages in the provision of bioprocessing technology and solutions. It operates through the following geographical segments: United States; Sweden; United Kingdom; and Other. It also serve through the following product lines: Protein; Filtration; Chromatography; and Other.
